LOS ANGELES - Researchers at the National Institutes of Health are studying a promising antibody treatment for multisystem inflammatory syndrome in children (MIS-C), most commonly linked to COVID-19 infection.In a study published on Oct.
15, NIH researchers found that Intravenous immune globulin (IVIG) — a common treatment for MIS-C, worked by depleting inflammatory immune cells which exacerbate the symptoms of MIS-C.
MIS-C is a condition in which different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs, according to the NIH.
Symptoms of MIS-C include fever, abdominal pain, vomiting, diarrhea, neck pain, rash, bloodshot eyes and feeling tired.Cases of the rare syndrome have.